Back to Search
Start Over
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia
- Source :
- Cancer. 117:4831-4868
- Publication Year :
- 2011
- Publisher :
- Wiley, 2011.
-
Abstract
- BACKGROUND: Constitutive activation of signal transducer and activator of transcription-3 (STAT3) was detected in blasts from approximately 50% of patients with acute myeloid leukemia (AML) and was correlated with an adverse outcome. In vitro treatment of AML blasts with arsenic trioxide (ATO) down-regulated STAT3 activity within 6 hours associated with a reduced viability within 48 hours. METHODS: A phase 1 clinical trial to evaluate the biologically effective dose and/or the maximally tolerated dose (MTD) of ATO in vivo in conjunction with high-dose cytarabine (Hidac) and idarubicin (Ida) in patients with AML aged
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Myeloid
business.industry
medicine.medical_treatment
Phases of clinical research
Myeloid leukemia
medicine.disease
chemistry.chemical_compound
Leukemia
medicine.anatomical_structure
chemistry
hemic and lymphatic diseases
Internal medicine
Immunology
medicine
Cytarabine
Idarubicin
Arsenic trioxide
business
medicine.drug
Subjects
Details
- ISSN :
- 0008543X
- Volume :
- 117
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi...........2ab934dd4e4f7f6ac5081dc11adca822